Article publishing option Open Access

Limited-Time Complimentary Open Access Offer Get free Open Access by submitting your article on or before January 31st, 2026. This offer applies to general articles only. This journal's open access policy.

Current Alzheimer Research

Journal Impact Factor: 1.9
Scopus Cite Score: 3.6

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed

View All
Aims and Scope:
Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies, letter articles, case reports, systematic reviews, and editorials on all areas of Alzheimer's disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, diagnosis and treatment strategies of Alzheimer's disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer's disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer's disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer's disease. Current Alzheimer Research provides a comprehensive 'bird's-eye view' of the current state of Alzheimer's research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.
Read more...
Start Submission Button Icon

Editor-in-Chief:

  • Thomas V. GroenDepartment of Cell, Developmental and Integrative Biology
    University of Alabama at Birmingham
    Birmingham, AL
    United States of America

ISSN: 1567-2050 (Print)

eISSN: 1875-5828 (Online)

Special Issues With Active Call for Papers

Submission closes on: Oct 09, 2026
Atypical Alzheimer’s disease: towards inclusion into disease-modifying clinical trials

Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic Alzheimer's disease patients will generalize to atypical variants. This issue will focus on: 1. gaining a better understanding of the factors that influence patterns and... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Neha Singh-Reilly
Co-Guest Editor(s): Dr. Irene Sintini
Start Submission
Submission closes on: Jul 02, 2026
Technology developments of medical imaging and artificial intelligence in cognitive impairment

Cognitive impairment refers to the impairment of brain functions such as memory, language, visual space, execution, and calculation. There are various causes of cognitive impairment, such as Alzheimer's disease, frontotemporal dementia, Prynne's disease, Lewy body dementia, Parkinson's disease, and Huntington's disease. So far, most of them do not have effective treatment methods, and early diagnosis and prediction are crucial for delaying the disease progression. Traditional diagnosis mainly relies on clinical manifestations, which are highly subjective.... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Chuanming Li
Co-Guest Editor(s): Dr. Xiaobo Lii
Start Submission
Submission closes on: Jun 18, 2026
The Gut Microbiome Landscape in Alzheimer’s Disease: Current Evidence and Controversies

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia globally. While amyloid-beta (Aβ) accumulation and tau pathology have long dominated mechanistic models of AD, emerging research underscores the central role of the gut-brain-microbiota axis in influencing disease onset, progression, and potentially, treatment outcomes. This thematic issue aims to explore how gut dysbiosis, intestinal permeability, and microbial metabolites contribute to neuroinflammation, amyloidogenesis, and blood-brain barrier dysfunction—key processes implicated in the... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Leonidas Panos
Start Submission
Submission closes on: Mar 20, 2026
Drug Discovery and Possible Therapeutic Developments in Neurological Disorders Alzheimer’s Disease and Tauopathy

A critical appraisal Alzheimer's disease (AD) is a devastating mental illness in society and the etiology and pathogenesis of AD are still poorly understood. One of the key hallmark pathological proteins of AD is tau, where the pathophysiology and the functional relationships between hyperphosphorylation of tau and synaptic damage in AD neurons are still challenging to modern biologists. The microtubule-associated protein (MAPT), tau plays an important role in maintaining the structure and stability of microtubules... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Pradeepkiran Jangampalli Adi
Co-Guest Editor(s): Dr. Munikumar Manne
Start Submission
Submission closes on: Feb 28, 2026
Ischemic proteomic and genomic changes in neurodegenerative diseases with special emphasis on Alzheimer's disease

Focal or global brain ischemia leads to neuronal death and neurodegeneration, which in turn results in the proteomic and genomic changes characteristic of Alzheimer's disease, including amyloid and tau protein alterations. Identical changes are caused by perinatal hypoxia, which intensifies changes in the brain later in life, leading to impaired cognitive functions. Thus, increasing evidence indicates that the pathologies caused by perinatal hypoxia and brain ischemia in adults are almost identical to neurodegenerative disease such... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Prof. Ryszard Pluta
Co-Guest Editor(s): Dr. Marzena Ułamek-Kozioł
Start Submission
Submission closes on: Feb 07, 2026
Alzheimer's Disease Blood Tests: Advancements and the Future of Point-of-Care

The recent FDA approval of lecanemab (Leqembi), the first treatment for Alzheimer’s disease targeting early stages and mild cognitive impairment, has brought renewed hope for the therapeutic future of this devastating condition. While the exact causes and mechanisms of Alzheimer’s disease remain obscure, there is an urgent consensus on the importance of early diagnosis—ideally well before symptoms fully manifest, which could significantly benefit treatment and care. Recent advances in ultrasensitive detection of biomarker proteins in... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Qiong Liu
Start Submission
Submission closes on: Feb 01, 2026
Network Pharmacology in Alzheimer's Disease

Alzheimer’s disease (AD) is a complex neurodegenerative disorder that leads to cognitive decline and memory loss, and remains a major challenge in modern medicine. Despite significant advancements in understanding its molecular mechanisms, effective treatments are still limited. The multifactorial nature of AD, driven by the interplay of multiple biological pathways, calls for innovative therapeutic strategies that move beyond traditional single-target approaches. This thematic issue explores the potential of various bioactive compounds in treating AD through... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Sarvesh Sabarathinam
Co-Guest Editor(s): Dr. Manoj Narasimhan
Start Submission
Submission closes on: Jan 23, 2026
Neuroinflammation and neurodegeneration resulting from brain injury

Neurodegeneration resulting from stroke, neurotrauma, subarachnoid hematoma, and other types of brain injury can lead to dementia and severe cognitive impairment. In all these conditions, the cellular and molecular mechanisms underlying the onset and development of neurodegeneration are expected to be fully elucidated. Recent studies suggest that these mechanisms include chronic inflammatory responses, immune regulation, production and deposition of pathological proteins and damage to the blood-brain barrier. However, there is still a lack of in-depth... see more

Impact Factor: 1.9
Guest Editor(s): Dr. Xintong Ge
Co-Guest Editor(s): Dr. Cheng Wei,Dr. Mengtian Guo,Dr. Conglin Wang
Start Submission